Recent Collaborations And Pipeline Scenario For TIGIT Inhibitors

When TIGIT is combined with other immunotherapies, the TIGIT targeting proves to be more effective. TIGIT has a broad expression on lymphocytes, thus making it a crucial immune checkpoint with the potential to inhibit each step of the cancer immunity circle.

TIGIT, short form for T-cell immunoreceptor with Ig and ITIM domains, is a transmembrane glycoprotein receptor made of Ig-like V-type domain within its cytoplasmic domain and an ITIM in its extracellular domain. Several clinical studies having combination treatments have been started that study TIGIT-blockade in cancer. These clinical studies have proved TIGIT to be a suitable target for cancer treatment. Presently, there are six active clinical trials whose outcomes are eagerly anticipated. 

Recent Collaboration Assessment:

• In 2018, AstraZeneca purchased an exclusive license to COM902 for the development of multi-specific and bispecific antibody products.
• In May 2020, Gilead and Arcus agreed on co-developing and co-commercializing anti-TIGIT domvanalimab.
• In May 2021, Bristol Myers Squibb purchased an exclusive license to Agenus’ AGEN1777, a bispecific antibody that blocks TIGIT and a second undisclosed target.
• In June 2021, iTeos Therapeutics and GlaxoSmithKline agreed on co-developing and co-commercializing EOS-488, an anti-TIGIT monoclonal antibody. EOS-488 is phase I as of now, and can be a potential treatment for cancer patients.

The Pipeline Scenario For TIGIT Inhibitors:

• Ociperlimab +  Tislelizumab, By BeiGene.
• Tiragolumab +  atezolizumab , By Genentech.
• Domvanalimab +  Zimberelimab, By Arcus Biosciences.
• MK-7684A (pembrolizumab/vibostolimab), By Merck Sharp & Dohme.
• EOS 448 +  anti-PD1 +  Inupadenant, By iTeos Therapeutics.
• BMS 986207, By Bristol-Myers Squibb.
• CRC01 +  fludarabine and cyclophosphamide, By Curocell.
• Etigilimab +  Nivolumab, By Mereo BioPharma.
• M-6223 +  Bintrafusp alfa, By Merck KGaA.
• BAT-6005, By Bio-Thera Solutions.
• AB-308 +  AB122, By Arcus Biosciences.
• COM-902 +  COM701, By Compugen.
• AGEN 1327, By Agenus.
• AGEN 1777 +  PD-1 Inhibitor, By Agenus.
• TSRF-786-C, By Tasrif Pharmaceutical.
• PH 804, By Phio Pharmaceuticals.

Source: Insight of T cell immunoglobulin and ITIM domain (TIGIT) Inhibitor, By Delveinsight.